Background The cardiovascular complications of cancer therapeutics are the focus of the
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …

Although the incidence of gastric cancer has fallen steadily in developed countries over the
past 50 years, outcomes in Western countries remain poor, primarily due to the advanced …

Background Peri-operative chemotherapy and surgery is a standard of care for patients with
resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody …

Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs,
including conventional chemotherapeutics as well as targeted anticancer agents, originates …

The long-established notion that apoptosis would be immunologically silent, and hence it
would go unnoticed by the immune system, if not tolerogenic, and hence it would actively …

Gastric cancer is one of the most common digestive system tumors in China, and locally
advanced gastric cancer (LAGC) accounts for a high proportion of newly diagnosed cases …

The chemokine (CXC motif) ligand 1 (CXCL1) regulates tumor–stromal interactions and
tumor invasion. However, the precise role of CXCL1 on gastric tumor growth and patient …

In 1997, the first monoclonal antibody (MoAb), the chimeric anti‐CD20 molecule rituximab,
was approved by the US Food and Drug administration for use in cancer patients. Since …

Although surgical resection remains the only potentially curative treatment for gastric cancer
(GC), poor long-term outcomes with resection alone compel a multimodality approach to this …

Arterial ischemia and hemorrhage are associated with bevacizumab, an inhibitor of vascular
endothelial growth factor that is widely used to treat many types of cancers. As specific types …